Plasma metabolites may inhibit childhood obesity by regulating ferroptosis through SMPD1 and SIRT3
November 17, 2025 / Childhood obesity ferroptosis / Plasma metabolite biomarkers / SMPD1 SIRT3 obesity / Genetic obesity risk / Pediatric metabolic pathways
Mendelian randomization analysis reveals that plasma metabolites may influence childhood obesity by regulating ferroptosis through genes like SMPD1 and SIRT3, suggesting ferroptosis as a novel mechanistic pathway and therapeutic target for pediatric obesity prevention and intervention.
Blocking gene improves metabolic health in obese mice without weight loss
November 12, 2025 / FAM20C insulin resistance / Obesity inflammation target / Metabolic health improvement / Visceral fat reduction / Type 2 diabetes mechanisms
Blocking the fat‑cell kinase FAM20C in obese mice reduced inflammation, improved insulin sensitivity, and decreased visceral fat without weight loss, identifying FAM20C—and its target CNPY4—as promising therapeutic targets for metabolic disease and type 2 diabetes prevention.
Oral GLP-1 Pills for Weight Loss: How Orforglipron Works
November 17, 2025 / Orforglipron weight loss / Oral GLP-1 therapy / Non-peptide GLP-1RA / Appetite glucose regulation / Cardiometabolic health drug
Orforglipron, a once-daily oral non-peptide GLP-1 receptor agonist, effectively promotes weight loss and improves glycemic and cardiometabolic parameters without injections. It activates cAMP signaling, enhances insulin secretion, suppresses glucagon, and delays gastric emptying with a favorable tolerability profile.
Medifast Scientific & Clinical Affairs Team Showcases New Research in Metabolic Health at ObesityWeek Conference
November 13, 2025 / GLP-1 weight plateau / Sleep metabolic health / Medifast obesity research / Lifestyle obesity treatment / Metabolic dysfunction prevention
At ObesityWeek 2025, Medifast presented research linking long-term GLP-1 therapy with weight regain post-discontinuation and highlighted poor sleep as a key risk factor for metabolic dysfunction—reinforcing the need for holistic strategies in obesity and metabolic health management.
A COM-B-guided lifestyle intervention reduces metabolic syndrome in overweight and obese adolescents: a multiphase study in Vietnam
November 17, 2025 / Adolescent metabolic syndrome / COM-B obesity intervention / Vietnam child health / School-based lifestyle program / Cardiometabolic risk reduction
A 12-month school-based COM-B lifestyle intervention in Vietnamese adolescents with obesity significantly reversed metabolic syndrome in 71.7% of participants, improving lipid profiles and health behaviors—demonstrating a feasible, scalable strategy for cardiometabolic risk reduction in low-resource settings.
Weight Loss Restores Vitamin D Metabolism in Obese Mice
November 15, 2025 / Vitamin D obesity link / Weight loss vitamin D / Adipose tissue metabolism
Weight loss in obese mice restored both circulating and adipose tissue vitamin D metabolism, reversing enzymatic imbalances that contribute to deficiency—highlighting obesity’s role in disrupting vitamin D pathways beyond fat sequestration and supporting metabolic interventions over supplementation alone.
HERP constrains white adipose expansion and inflammation by STEAP4 stabilization
November 17, 2025 / HERP STEAP4 obesity / White adipose inflammation / Adipogenesis metabolic disorder
HERP stabilizes STEAP4 to suppress adipogenesis and inflammation in white adipose tissue. HERP deficiency worsens obesity and metabolic dysfunction, while enhancing STEAP4 reverses these effects—highlighting the HERP–STEAP4 axis as a potential therapeutic target for obesity-related disorders.
Pennington Biomedical encourages “small shifts” for a healthier, more energized holiday season
November 14, 2025 / Holiday health tips / Mindful eating habits / Portion control holidays / Metabolic health strategies / Pennington Biomedical campaign
Pennington Biomedical promotes “small shifts” during the holidays—like balanced meals, mindful eating, portion control, and post-meal movement—to support metabolic health, reduce food waste, and maintain energy, reinforcing that modest lifestyle changes can lead to lasting health benefits.
Dash diet cuts diabetes complications by targeting blood pressure kidney health and inflammation
The DASH diet improves metabolic health in diabetes by lowering blood pressure, reducing renal injury, improving lipids and insulin resistance, and decreasing inflammation—offering modest but clinically meaningful glycemic benefits and broad cardiometabolic protection.
Early-life ketone signaling may shape long-term metabolic health
November 12, 2024 / Ketone signaling development / Neonatal beige fat / β-hydroxybutyrate metabolism / Infant nutrition obesity / Epigenetic adipose programming
Researchers discovered that ketone bodies, especially β-hydroxybutyrate during lactation, epigenetically program beige fat development in infants, influencing lifelong metabolic health—highlighting early-life ketogenesis as a critical window for obesity prevention and energy regulation through thermogenic fat activation.
Nutritional supplement could help with fat metabolism activation therapies
November 12, 2025 / Fat metabolism activation / Natural obesity supplement / Insulin sensitivity improvement
Pennington Biomedical researchers developed a GRAS-designated supplement (naringenin, beta carotene, artepillin C) that reprograms fat cells to boost energy expenditure, reduce liver fat, and improve insulin sensitivity—offering a natural, side-effect-free strategy for treating obesity and metabolic diseases.
Nutritional supplement could help with fat metabolism activation therapies
November 12, 2025 / Fat metabolism supplement / Natural weight loss therapy / Insulin sensitivity booster
Pennington Biomedical researchers developed a GRAS-approved supplement (naringenin, beta carotene, artepillin C) that reprograms fat cells to enhance triglyceride metabolism, boost energy expenditure, reduce liver fat, and improve insulin sensitivity—offering a natural, side-effect-free strategy for obesity and metabolic disease management.
Fat Hormone Found To Activate Cancer-Promoting Metabolic Pathway
November 11, 2025 / Leptin breast cancer / Obesity cancer link / SCD tumor growth
New research reveals that leptin activates the enzyme SCD in estrogen receptor-positive breast cancer, promoting tumor growth and motility. This leptin–SCD axis links obesity to cancer progression and may serve as a prognostic marker and therapeutic target.
Visceral Lipids Outshine Insulin Scores in Metabolic Risk
November 15, 2025 / Visceral fat risk / Lipid accumulation product / Metabolic syndrome prediction
Visceral fat, measured via lipid accumulation product (LAP), outperforms insulin resistance scores in predicting metabolic syndrome risk, particularly in Northern Chinese adults—highlighting visceral adiposity as a critical and more accurate marker for early metabolic dysfunction assessment.
Four Pennington Biomedical researchers recognized among the world’s most highly cited researchers
November 13, 2025 / Highly cited researchers / Pennington obesity science / Metabolic health leadership
Four Pennington Biomedical researchers—Drs. Heymsfield, Katzmarzyk, Ravussin, and Ryan—were named among the world’s most highly cited scientists, recognizing their transformative impact on obesity, metabolism, and public health through decades of influential, high-impact scientific research.
The Biology Beneath the Weight — Why Obesity Requires Metabolic Thinking
November 14, 2025 / Obesity metabolic disease / Appetite hormone disruption / Leptin insulin resistance
Obesity is a chronic metabolic disease driven by disrupted hormonal and neural pathways, including leptin resistance, insulin dysfunction, and hypothalamic dysregulation—not personal failure—requiring care strategies that target underlying biology, stress, sleep, and metabolic adaptation for effective treatment.
AI Pathology Shows Efruxifermin Benefits in MASH, Cirrhosis
November 13, 2025 / Efruxifermin / MASH cirrhosis treatment / Liver fibrosis reduction
AI-driven pathology confirmed that efruxifermin significantly reduces liver fibrosis and septa area in patients with MASH and compensated cirrhosis, suggesting broad antifibrotic effects beyond conventional histology, with potential to improve liver outcomes across fibrosis stages.
Combination of THU/ALK-5i exhibits profound anti-MASH activity through suppression of lipogenesis and fibrogenesis
November 14, 2025 / MASH liver cancer / Fibrotic immune phenotype / HCC recurrence risk / Hot cold fibrosis / Immunotherapy liver fibrosis
The combination of tetrahydrocurcumin (THU) and ALK-5 inhibitor EW-7197 significantly reduced liver fibrosis and steatohepatitis in MASH models by suppressing lipogenesis and fibrogenesis, showing synergistic effects and therapeutic promise for future MAFLD/MASH treatment strategies.
Understanding leptin’s dual function in MAFLD pathogenesis
November 14, 2025 / Leptin / MAFLD pathogenesis / Insulin resistance / Liver fibrosis / Adipokine signaling
Leptin plays a dual role in MAFLD, acting as both a metabolic regulator and disease promoter. Leptin resistance impairs lipid metabolism, promotes inflammation and fibrosis, and worsens insulin resistance, making leptin signaling a complex but promising therapeutic target.
Ultra-processed foods quietly push young adults toward prediabetes
November 17, 2025 / Ultra-processed foods / Prediabetes risk / Insulin resistance / Young adult metabolism / Type 2 diabetes
A USC study found that increased consumption of ultra-processed foods (UPFs) in young adults significantly raises the risk of prediabetes and insulin resistance over four years, highlighting early metabolic disruption before overt disease onset.